Eron JJ, et al. - Researchers undertook phase-3, randomized, active-controlled, double-blind, international, multicenter, noninferiority study (NCT02431247) assessing the efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infected adults. Researchers noted that D/C/F/TAF resulted in a high virologic suppression rate (91.4%) and was noninferior to darunavir/cobicistat with F/TDF. Furthermore, in combination with darunavir/cobicistat, D/C/F/TAF showed the bone and renal safety advantages of TAF.